Can genetic variation, high omega-6 intake, or poor fat absorption lower EPA status?

An individual's systemic eicosapentaenoic acid (EPA) status is governed by a complex interplay of genetic predisposition, dietary fatty acid ratios, and digestive efficiency. For a 60-year-old male, understanding these distinct pathways can help optimize cardiovascular, cognitive, and inflammatory health.

Genetic and metabolic factors

• Desaturase gene variants: Polymorphisms in the FADS1 gene, particularly the minor allele of rs174547, significantly compromise endogenous EPA synthesis. FADS1 encodes Δ5-desaturase, a rate-limiting enzyme that converts alpha-linolenic acid (ALA) into EPA. Minor-allele carriers of rs174547 exhibit reduced enzymatic activity, resulting in a 38% to 42% reduction in baseline plasma and red blood cell EPA levels compared to wild-type homozygotes, alongside a blunted response to omega-3 supplementation.
• Fatty acid transport: While variations in the transport protein CD36 (such as the promoter variant rs1761667) alter oral fat perception and general lipid metabolism, a direct link showing that these variants compromise systemic human EPA levels remains clinically unproven, despite strong mechanistic plausibility.

Dietary substrate competition

• Enzymatic competition: High dietary intake of omega-6 fatty acids, primarily linoleic acid (LA), directly competes with omega-3 ALA for the shared desaturase and elongation enzymes (FADS1 and FADS2).
• Suppressed conversion rates: Endogenous conversion of ALA to EPA is naturally inefficient in humans, typically yielding less than 10%. When diets are high in omega-6 substrates, this conversion efficiency is further suppressed by approximately 40% to 50% due to enzymatic crowding, shifting the metabolic pathway toward arachidonic acid synthesis at the expense of EPA.

Digestive and absorptive efficiency

• Malabsorption pathways: Efficient absorption of dietary EPA requires adequate pancreatic lipases and bile salts for micellar solubilization in the small intestine. Conditions such as pancreatic exocrine insufficiency impair this process, leading to lower baseline plasma EPA levels.
• Formulation sensitivity: Standard dietary fats and ethyl ester fish oil supplements rely heavily on pancreatic lipase activity and are highly vulnerable to malabsorption. In contrast, specialized delivery systems, such as emulsified or monoacylglycerol-enriched formulations, can bypass some of these digestive barriers to improve EPA bioavailability.

Bottom line

Low systemic EPA status can be driven by genetic variations in the FADS1 pathway, high dietary omega-6 intake that competitively blocks ALA conversion, or impaired fat digestion. Optimizing EPA levels in compromised individuals requires minimizing competing dietary omega-6 fatty acids and utilizing pre-formed, highly bioavailable omega-3 formulations.